mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
PDF) Modified mRNA Vaccines Protect against Zika Virus Infection
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
COVID-19 vaccine development and a potential nanomaterial path forward | Nature Nanotechnology
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. - Abstract - Europe PMC
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moderna Therapeutics — Wikipédia
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
Current Status of COVID‐19 (Pre)Clinical Vaccine Development - Ye - 2020 - Angewandte Chemie International Edition - Wiley Online Library
PDF) Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Crowd fund launched for 'Battlestar Galactica' actor Michael Hogan after brain injury
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
Moderna's coronavirus vaccine shows encouraging early results - The Washington Post
COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma
